文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PROSEVEN试验:MR引导前列腺SBRT七日方案首次结果

Proseven trial: MR-guided prostate stereotactic body radiotherapy in seven days - First results.
PubMed 文献 · Radiother Oncol · 2025-10-17

PROSEVEN是一项II期试验,评估0.35T MR-Linac在七天内实施前列腺SBRT并同步整合推量至GTV的急性毒性。132例低危(12.1%)、中危(66.6%)和局限高危(21.2%)前列腺癌患者接受PTV 36 Gy/5次、CTV 40 Gy、GTV最高42 Gy。未观察到3级急性GU或GI毒性,急性2级GU毒性35%,2级GI毒性5%。

要点

  • 七天内MR引导前列腺SBRT可行,85%患者接受GTV同步整合推量。
  • 未观察到3级急性GU或GI毒性,2级GU毒性35%、GI毒性5%。
  • 仅64.4%患者在规定的7天OTT内完成治疗。

核心结论

  • MRgRT引导下七天内前列腺SBRT联合GTV同步整合推量,急性GU毒性可接受且急性GI毒性低。

研究设计与样本

  • II期PROSEVEN试验,经布鲁塞尔UZ伦理委员会批准,已完成入组,5年随访进行中。
  • 132例低危(12.1%)、中危(66.6%)和局限高危(21.2%)前列腺癌患者纳入分析。

主要发现

  • PTV处方36 Gy/5次,CTV 40 Gy,前列腺内肿瘤GTV同步整合推量最高42 Gy,使用0.35T MR-Linac在七天内实施。
  • 85%患者接受GTV同步整合推量,64.4%患者在规定的7天OTT内完成治疗。
  • 诊断时中位PSA为9.43 ng/ml。
  • 未观察到3级急性GU或GI毒性;急性2级GU毒性发生率35%,急性2级GI毒性发生率5%。

关键数值与推荐

  • 主要终点为CTCAE v5.0评估的临床医生报告急性GU和GI毒性(2级及以上)发生率。
  • 次要终点包括患者报告结局(PROMs)。

临床怎么用

  • 七天内MR引导前列腺SBRT联合GTV同步整合推量可作为改善患者舒适度和治疗依从性的策略,急性GU毒性可接受、急性GI毒性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Reducing the overall treatment duration of prostate SBRT has the potential to improve patient comfort and treatment compliance. Additionally, focal boosting to the gross tumor volume (GTV) is of interest to enhance oncologic outcomes. The phase II PROSEVEN trial (MR-guided prostate stereotactic body radiotherapy in seven days) combined both strategies, utilizing MR-guided radiotherapy (MRgRT) to deliver treatment. MATERIALS AND METHODS: Treatment delivered 36 Gy in five fractions to the planning target volume (PTV), 40 Gy to the clinical target volume (CTV), and up to 42 Gy as a simultaneous integrated boost (SIB) to the intraprostatic tumor (GTV). This was administered using a 0.35-Tesla MR-Linac over a seven-day period. The primary endpoint was the incidence of clinician-reported acute GU and GI toxicity of grade 2 or higher, assessed using CTCAE v5.0. Secondary endpoints included patient-reported outcomes (PROMs). This phase II Proseven trial, approved by the Ethics Committee of UZ Brussels, has completed recruitment with five-year follow-up ongoing. RESULTS: A total of 132 patients with low (12.1 %), intermediate (66.6 %), and limited high-risk (21.2 %) prostate cancer were included. The median PSA at diagnosis was 9.43 ng/ml. SIB to the GTV was performed in 85 % of patients, and 64.4 % completed the treatment within the specified 7 days OTT. No grade 3 acute GU or GI toxicity was observed. Acute Grade 2 GU toxicity occurred in 35 %. Acute Grade 2 GI toxicity occurred in 5 %. CONCLUSION: Prostate SBRT with SIB to the GTV in seven days using MRgRT demonstrated acceptable acute GU toxicity rates and low acute GI toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Vanspeybroeck B, Bezuidenhout J, Soete G, et al. Proseven trial: MR-guided prostate stereotactic body radiotherapy in seven days - First results. Radiother Oncol. 2025. PMID: 41110802. doi:10.1016/j.radonc.2025.111208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。